[1] Siegel R, Naishadham D, Jemal A. Cancer statistics,2012[J]. CA Cancer J Clin, 2012,62(1): 1029.
[2] Mazzone P, Mekhail T. Current and emerging medical treatments for nonsmall cell lung cancer: a primer for pulmonologists[J]. Respir Med, 2012,106(4): 473492.
[3] Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer[J]. Am J Pathol, 2011, 178(3): 989996.
[4] Duda DG, Ancukiewicz M, Isakoff SJ, et al. Seeds and soil: unraveling the role of local tumor stroma in distant metastasis[J]. J Natl Cancer Inst, 2014, 106(8): dju187.
[5] Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cellsbiology and biomarkers[J]. Nat Rev Clin Oncol, 2014, 11(3): 129144.
[6] Burki TK. Late detection of lung cancer[J]. Lancet Oncol, 2014, 15(13): e590.
[7] Ilie M, Hofman V, LongMira E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10): e111597.
[8] Harouaka RA, Zhou MD, Yeh YT, et al. Flexible micro spring array device for highthroughput enrichment of viable circulating tumor cells[J]. Clin Chem, 2014, 60(2): 323333.
[9] Weight RM, Viator JA. Detection of circulating tumor cells by photoacoustic flowmetry[J]. Methods Mol Biol, 2014, 1102: 655663.
[10] Li Q, Qi H, Zhou HX, et al. Detection of micrometastases in peripheral blood of nonsmall cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay[J]. Int J Nanomedicine, 2011, 6: 21752181.
[11] Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmallcell lung cancer[J]. J Clin Oncol, 2011, 29(12): 15561563.
[12] Li J, Shi SB, Shi WL, et al. LUNX mRNApositive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer[J]. Transl Res, 2014, 163(1): 2735.
[13] Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827835..
[14] Zhu WF, Li J, Yu LC, et al. Prognostic value of EpCAM/MUC1 mRNApositive cells in nonsmall cell lung cancer patients[J]. Tumour Biol, 2014, 35(2): 12111219.
[15] Du YJ, Li J, Zhu WF, et al. Survivin mRNAcirculating tumor cells predict treatment efficacy of chemotherapy and survival for advanced nonsmall cell lung cancer patients[J]. Tumour Biol, 2014, 35(5): 44994507.
[16] Juan O, Vidal J, Gisbert R, et al. Prognostic significance of circulating tumor cells in advanced nonsmall cell lung cancer patients treated with docetaxel and gemcitabine[J]. Clin Transl Oncol, 2014, 16(7): 637643.
[17] Dorsey JF, Kao GD, MacArthur KM, et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of nonsmall cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results[J]. Cancer, 2015, 121(1): 139149.
[18] Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 23912401.
[19] Hashimoto M, Tanaka F, Yoneda K, et al. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer[J]. Interact Cardiovasc Thorac Surg, 2014, 18(6): 775783.
[20] Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J]. Science, 2014, 345(6193): 216220.
[21] Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science, 2013, 339(6119): 580584.
[22] Comen E, Norton L, Massagué J. Clinical implications of cancer selfseeding[J]. Nat Rev Clin Oncol, 2011, 8(6): 369377.
[23] Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a realtime liquid biopsy for treatment[J]. PLoS One, 2014, 9(8): e103883.
[24] Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALKpositive nonsmallcell lung cancer[J]. J Clin Oncol, 2013, 31(18):22732281. |